Clin Endosc.  2018 Jan;51(1):37-49. 10.5946/ce.2017.141.

Colorectal Cancer Screening—Who, How, and When?

• Bevan R
• Rutter MD

• KMID: 2403631
• DOI: http://doi.org/10.5946/ce.2017.141

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. It is amenable to screening as it occurs in premalignant, latent, early, and curable stages. PubMed, Cochrane Database of Systematic Reviews, and national and international CRC screening guidelines were searched for CRC screening methods, populations, and timing. CRC screening can use direct or indirect tests, delivered opportunistically or via organized programs. Most CRCs are diagnosed after 60 years of age; most screening programs apply to individuals 50-75 years of age. Screening may reduce disease-specific mortality by detecting CRC in earlier stages, and CRC incidence by detecting premalignant polyps, which can subsequently be removed. In randomized controlled trials (RCTs) guaiac fecal occult blood testing (gFOBt) was found to reduce CRC mortality by 13%-33%. Fecal immunochemical testing (FIT) has no RCT data comparing it to no screening, but is superior to gFOBt. Flexible sigmoidoscopy (FS) trials demonstrated an 18% reduction in CRC incidence and a 28% reduction in CRC mortality. Currently, RCT evidence for colonoscopy screening is scarce. Although not yet corroborated by RCTs, it is likely that colonoscopy is the best screening modality for an individual. From a population perspective, organized programs are superior to opportunistic screening. However, no nation can offer organized population-wide colonoscopy screening. Thus, organized programs using cheaper modalities, such as FS/FIT, can be tailored to budget and capacity.

Keyword

Colorectal neoplasms; Screening; Colonoscopy

MeSH Terms

Budgets
Colonoscopy
Colorectal Neoplasms*
Guaiac
Incidence
Mass Screening
Mortality
Occult Blood
Polyps
Sigmoidoscopy
Guaiac

Reference

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: IARC;c2012. [cited 2017 Sep 5]. Available from: http://globocan.iarc.fr/Default.aspx.

2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59:366–378.

3. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010; 8:8–61.

4. Cancer Research UK. Bowel cancer statistics [Internet]. London: Cancer Research UK;c2015. [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer?_ga=2.199557997.216204478.1517035023-396171367.1516104333#heading-Zero.

5. Cancer Research UK. Bowel cancer incidence statistics [Internet]. London: Cancer Research UK;c2015. [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence?_ga=2.130656591.172763994.1517148794-396171367.1516104333#heading-Eleven.

6. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009; 18:1688–1694.

7. Valori R, Rutter M, Aravani A, Rashbass J, Vernon S, Morris EJA. National early diagnosis initiatives and their impact on the incidence of colorectal cancer in England. United European Gastroenterol J. 2016; 4:800–811.

8. Welch HG, Robertson DJ. Colorectal cancer on the decline--why screening can’t explain it all. N Engl J Med. 2016; 374:1605–1607.

9. Gavin DR, Valori RM, Anderson JT, Donnelly MT, Williams JG, Swarbrick ET. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut. 2013; 62:242–249.

10. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968; 65:281–393.

11. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89:845–860.

12. Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer. 1992; 70(6 Suppl):1727–1731.

13. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011; 42:1–10.

14. Cancer Research UK. Cancer incidence for all cancers combined [Internet]. London: Cancer Research UK;c2015. [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/all-cancers-combined?_ga=2.34114657.172763994.1517148794-396171367.1516104333.

15. Rees CJ, Bevan R. The national health service bowel cancer screening program: the early years. Expert Rev Gastroenterol Hepatol. 2013; 7:421–437.

16. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009; 104:739–750.

17. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64:1637–1649.

18. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010; 59:666–689.

19. Rex DK, Bond JH, Winawer S, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol. 2002; 97:1296–1308.

20. U.S. Preventive Services Task Force. Preventive Services Task Force. Screening for colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2008; 149:627–637.

21. Fletcher RH. Diet for fecal occult blood test screening: help or harm? Eff Clin Pract. 2001; 4:180–182.

22. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012; 26:131–147.

23. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007; (1):CD001216.

24. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348:1472–1477.

25. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult- blood test. Lancet. 1996; 348:1467–1471.

26. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999; 91:434–437.

27. Kewenter J, Brevinge H, Engarås B, Haglind E, Ahrén C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol. 1994; 29:468–473.

28. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut. 2012; 61:1439–1446.

29. Leuraud K, Jezewski-Serra D, Viguier J, Salines E. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol. 2013; 37:959–967.

30. Pitkäniem J, Seppä K, Hakama M, et al. Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland. BMJ Open Gastroenterol. 2015; 2:e000034.

31. Paimela H, Malila N, Palva T, Hakulinen T, Vertio H, Järvinen H. Early detection of colorectal cancer with faecal occult blood test screening. Br J Surg. 2010; 97:1567–1571.

32. Steele RJ, McClements PL, Libby G, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut. 2009; 58:530–535.

33. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen. 2005; 12:28–32.

34. Katičić M, Antoljak N, Kujundžić M, et al. Results of national colorectal cancer screening program in Croatia (2007-2011). World J Gastroenterol. 2012; 18:4300–4307.

35. Geraghty J, Butler P, Seaman H, et al. Optimising faecal occult blood screening:retrospective analysis of NHS bowel cancer screening data to improve the screening algorithm. Br J Cancer. 2014; 111:2156–2162.

36. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013; (9):CD009259.

37. Bretthauer M. Colorectal cancer screening. J Intern Med. 2011; 270:87–98.

38. von Wagner C, Baio G, Raine R, et al. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol. 2011; 40:712–718.

39. Palmer CK, Thomas MC, von Wagner C, Raine R. Reasons for non-uptake and subsequent participation in the NHS bowel cancer screening programme: a qualitative study. Br J Cancer. 2014; 110:1705–1711.

40. Bradley DT, Treanor C, McMullan C, Owen T, Graham A, Anderson D. Reasons for non-participation in the Northern Ireland bowel cancer screening programme: a qualitative study. BMJ Open. 2015; 5:e008266.

41. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003; 53:44–55.

42. Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J. 2013; 1:198–205.

43. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta- analysis. Ann Intern Med. 2014; 160:171.

44. Kapidzic A, van Roon AH, van Leerdam ME, et al. Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut. 2017; 66:118–123.

45. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009; 100:1103–1110.

46. Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended? Gut. 2017; 66:1262–1267.

47. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology. 2012; 142:422–424.

48. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135:82–90.

49. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010; 59:62–68.

50. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014; 312:606–615.

51. Schreuders EH, Grobbee EJ, Spaander MC, Kuipers EJ. Advances in fecal tests for colorectal cancer screening. Curr Treat Options Gastroenterol. 2016; 14:152–162.

52. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375:1624–1633.

53. Hoff G, Grotmol T, Skovlund E, Bretthauer M; Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009; 338:b1846.

54. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial--SCORE. J Natl Cancer Inst. 2011; 103:1310–1322.

55. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366:2345–2357.

56. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002; 359:1291–1300.

57. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol. 2003; 38:635–642.

58. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014; 348:g2467.

59. Holme Ø, Schoen RE, Senore C, et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ. 2017; 356:i6673.

60. Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK flexible sigmoidoscopy screening randomised controlled trial. Lancet. 2017; 389:1299–1311.

61. Bevan R, Rubin G, Sofianopoulou E, Patnick J, Rees CJ. Implementing a national flexible sigmoidoscopy screening program: results of the English early pilot. Endoscopy. 2015; 47:225–231.

62. Neilson LJ, Bevan R, Nickerson C, et al. Bowelscope-results from the pilot sites. Gut. 2015; 64(Suppl 1):A370.

63. Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ. 2015; 350:h1662.

64. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy”--SCORE. J Natl Cancer Inst. 2002; 94:1763–1772.

65. Masseria C. Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment. Eur J Health Econ. 2010; 10 Suppl 1:S41–S49.

66. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut. 2017; 66:1631–1644.

67. von Wagner C, Bowyer H, Rees CJ, Atkin W, Wardle J. Patient-reported experience of comfort and dignity in flexible sigmoidoscopy: data from the NHS bowel scope screening pilot. Gut. 2014; 63(Suppl 1):A137.

68. Morris EJ, Rutter MD, Finan PJ, Thomas JD, Valori R. Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably depending on the method used to calculate them: a retrospective observational population-based study of PCCRC in the English national health service. Gut. 2015; 64:1248–1256.

69. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014; 370:1298–1306.

70. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010; 362:1795–1803.

71. Bowles CJ, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut. 2004; 53:277–283.

72. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS bowel cancer screening programme. Gut. 2012; 61:1050–1057.

73. Regula J, Zagorowicz E, Butruk E. Implementation of a national colorectal cancer screening program. Curr Colorectal Cancer Rep. 2006; 2:25–29.

74. Kaminski MF, Kraszewska E, Rupinski M, Laskowska M, Wieszczy P, Regula J. Design of the polish colonoscopy screening program: a randomized health services study. Endoscopy. 2015; 47:1144–1150.

75. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366:697–706.

76. Kaminski MF, Bretthauer M, Zauber AG, et al. The NordICC study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012; 44:695–702.

77. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993; 329:1977–1981.

78. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001; 48:812–815.

79. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007; 56:677–684.

80. Rutter MD, Nickerson C, Rees CJ, Patnick J, Blanks RG. Risk factors for adverse events related to polypectomy in the English bowel cancer screening programme. Endoscopy. 2014; 46:90–97.

81. Bevan R, Nickerson C, Patnick J, et al. Bowelscope: early results from the pilot sites. Gut. 2014; 63(Suppl 1):A145.

82. Ghanouni A, Plumb A, Rees CJ, et al. Patients’ experience of colonoscopy in the English bowel cancer screening programme. Gut. 2014; 63(Suppl 1):A137–A138.

83. Plumb AA, Ghanouni A, Rees CJ, et al. Comparison of patient experience of colonoscopy and CT colonography in the English bowel cancer screening programme. Gut. 2014; 63(Suppl 1):A136–A137.

84. Spada C, Hassan C, Galmiche JP, et al. Colon capsule endoscopy: European society of gastrointestinal endoscopy (ESGE) guideline. Endoscopy. 2012; 44:527–536.

85. Spada C, Hassan C, Marmo R, et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol. 2010; 8:516–522.

86. Rokkas T, Papaxoinis K, Triantafyllou K, Ladas SD. A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps. Gastrointest Endosc. 2010; 71:792–798.

87. Sacher-Huvelin S, Coron E, Gaudric M, et al. Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther. 2010; 32:1145–1153.

88. Triantafyllou K, Viazis N, Tsibouris P, et al. Colon capsule endoscopy is feasible to perform after incomplete colonoscopy and guides further workup in clinical practice. Gastrointest Endosc. 2014; 79:307–316.

89. Groth S, Krause H, Behrendt R, et al. Capsule colonoscopy increases uptake of colorectal cancer screening. BMC Gastroenterol. 2012; 12:80.

90. Alberti LR, Garcia DP, Coelho DL, De Lima DC, Petroianu A. How to improve colon cancer screening rates. World J Gastrointest Oncol. 2015; 7:484–491.

91. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet. 2013; 381:1185–1193.

92. von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol. 2011; 21:2046–2055.

93. von Wagner C, Ghanouni A, Halligan S, et al. Patient acceptability and psychologic consequences of CT colonography compared with those of colonoscopy: results from a multicenter randomized controlled trial of symptomatic patients. Radiology. 2012; 263:723–731.

94. Lin OS, Kozarek RA, Gluck M, et al. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies. J Gen Intern Med. 2012; 27:1349–1360.

95. Tappenden P, Eggington S, Richard Nixon R, Chilcott J, Sakai H, Karnon J. Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer [Internet]. Sheffield: University of Sheffield;c2004. [updated 2004 Sep; cited 2017 Sep 5]. Available from: https://pdfs.semanticscholar.org/09a0/8003b99c2abaf7d49308229a72ddfe54f677.pdf.

96. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening—age to begin, age to stop, and timing of screening intervals. Rockville (MD): Agency for Healthcare Research and Quality (US);2009.

97. Zauber AG, Knudsen AB, Carolyn R, et al. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach to inform the US preventive services task force. Gastroenterology. 2016; 150(4 Suppl 1):S46.

98. U.S. Preventive Services Task Force. Draft evidence review for colorectal cancer: screening [Internet]. Rockville (MD): U.S. Preventive Services Task Force;c2015. [updated 2015 Oct; cited 2017 Sep 5]. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review54/colorectal-cancer-screening2.

99. Harewood GC, Lawlor GO, Larson MV. Incident rates of colonic neoplasia in older patients: when should we stop screening? J Gastroenterol Hepatol. 2006; 21:1021–1025.

100. Brenner H. Colorectal cancer screening for older adults. BMJ. 2015; 350:h2029.

101. Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American college of physicians. Ann Intern Med. 2012; 156:378–386.

102. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US multi-society task force on colorectal cancer and the American cancer society. Gastroenterology. 2006; 130:1872–1885.